Abstract | BACKGROUND: METHODS: CRPC patients received patupilone 2.5 mg/m(2) weekly for 3 weeks of a 4-week cycle. Patients were required to have measurable disease or prostate-specific antigen (PSA) progression (levels>20 ng/ml). RESULTS: All 45 enrolled patients (median age, 69 years) were safety and response assessable. Sixty-four percent had previous chemotherapy (55% had previous taxane therapy). Patients received a median of three patupilone cycles. Patupilone was generally well tolerated. Ten (22%) patients experienced grade 3 diarrhea, six (13%) grade 3 fatigue, and one (2%) grade 3 neuropathy with no neutropenia or thrombocytopenia incidence. Six (13%) patients had >or= 50% decline in PSA (three had previous taxane therapy). No patient with measurable disease had a response. Median overall survival was 13.4 months. CONCLUSIONS: The safety profile of weekly patupilone in CRPC patients compares favorably with that of other microtubule inhibitors. At the dose and schedule tested, patupilone demonstrated minimal activity in CRPC.
|
Authors | A Hussain, R S DiPaola, A D Baron, C S Higano, N S Tchekmedyian, A R Johri |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 20
Issue 3
Pg. 492-7
(Mar 2009)
ISSN: 1569-8041 [Electronic] England |
PMID | 19087985
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Epothilones
- epothilone B
|
Topics |
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Epothilones
(adverse effects, therapeutic use)
- Humans
- Male
- Middle Aged
- Orchiectomy
- Prostatic Neoplasms
(drug therapy, surgery)
|